HBV Treatment
Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 14 September 2010 12:49
- Written by Liz Highleyman
Chronic hepatitis B treatment using entecavir (Baraclude) for 1 year is good, but 3 years is better, according to an international study published in the September 2010 issue of Hepatology. Patients who received at least 3 years of cumulative entecavir therapy showed substantial histological improvement on liver biopsies and experienced regression of liver fibrosis or cirrhosis.
Flares during HBV Treatment Do Not Predict Response, May Cause Liver Failure
- Details
- Category: HBV Treatment
- Published on Sunday, 12 September 2010 00:00
- Written by Liz Highleyman
Developing hepatic flares, or sudden increases in liver enzymes or viral load, while undergoing nucleoside/nucleotide analog therapy for chronic hepatitis B did not increase the likelihood of sustained viral clearance and led to decompensated liver failure in some patients, researchers reported in the July 2011 Journal of Viral Hepatitis.
How Long Do Chronic Hepatitis B Patients Need to be Treated to Sustain HBeAg Seroconversion?
- Details
- Category: HBV Treatment
- Published on Friday, 25 June 2010 12:49
- Written by Liz Highleyman
Longer treatment with antiviral agents such as lamivudine, and use of pegylated interferon for selected individuals, increases the likelihood of sustained hepatitis B "e" antigen (HBeAg) seroconversion and viral suppression in people with chronic hepatitis B, according to a set of recently published reports. Across the studies, younger age and longer duration of lamivudine therapy predicted sustained response. The data were not entirely consistent, however, indicating the need for further research in this area.
Adding Adefovir Works Better than Entecavir Monotherapy for Lamivudine-resistant Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 27 August 2010 12:49
- Written by Liz Highleyman
Addition of adefovir (Hepsera) to lamivudine (Epivir-HBV) proved to be a better "rescue therapy" strategy for patients with lamivudine-resistant hepatitis B virus (HBV) than switching to entecavir (Baraclude) monotherapy, according to a South Korean study published in the August 2010 Journal of Gastroenterology and Hepatology.
Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 04 June 2010 12:49
- Written by Dynavax
Dynavax Technologies announced this week that a Data Safety Monitoring Board has reviewed interim data from more than 2000 participants in 2 Phase 3 studies of the company's investigational hepatitis B vaccine, Hepislav, and determined that the trial may go forward without modification.
More Articles...
- HBeAg Decrease during Treatment Predicts Sustained Response to Pegylated Interferon for Chronic Hepatitis B
- EASL 2010: Spontaneous Undetectable Hepatitis B Virus DNA Is Uncommon, especially without HBeAg Clearance
- Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
- EASL 2010: Tenofovir (Viread) Effective for Treatment of Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (Hepsera)
Web Design and Development by